Top

Published in:

01-06-2009 | Research Paper

Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature

Authors: George J. Klarmann, Elaine M. Hurt, Lesley A. Mathews, Xiaohu Zhang, Maria A. Duhagon, Tashan Mistree, Suneetha B. Thomas, William L. Farrar

Published in: Clinical & Experimental Metastasis | Issue 5/2009

Abstract

Development of metastasis is a leading cause of cancer-induced death. Acquisition of an invasive tumor cell phenotype suggests loss of cell adhesion and basement membrane breakdown during a process termed epithelial-to-mesenchymal transition (EMT). Recently, cancer stem cells (CSC) were discovered to mediate solid tumor initiation and progression. Prostate CSCs are a subpopulation of CD44⁺ cells within the tumor that give rise to differentiated tumor cells and also self-renew. Using both primary and established prostate cancer cell lines, we tested the assumption that CSCs are more invasive. The ability of unsorted cells and CD44-positve and -negative subpopulations to undergo Matrigel invasion and EMT was evaluated, and the gene expression profiles of these cells were analyzed by microarray and a subset confirmed using QRT-PCR. Our data reveal that a subpopulation of CD44⁺ CSC-like cells invade Matrigel through an EMT, while in contrast, CD44⁻ cells are non-invasive. Furthermore, the genomic profile of the invasive cells closely resembles that of CD44⁺CD24⁻ prostate CSCs and shows evidence for increased Hedgehog signaling. Finally, invasive cells from DU145 and primary prostate cancer cells are more tumorigenic in NOD/SCID mice compared with non-invasive cells. Our data strongly suggest that basement membrane invasion, an early and necessary step in metastasis development, is mediated by these potential cancer stem cells.

Available only for authorised users

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458. doi:10.1038/nrc1098 PubMedCrossRef

Molloy T, van‘t Veer LJ (2008) Recent advances in metastasis research. Curr Opin Genet Dev 18:1–7CrossRef

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904. doi:10.1038/nm1469 PubMedCrossRef

Hugo H, Ackland ML, Blick T et al (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383. doi:10.1002/jcp.21223 PubMedCrossRef

Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822 PubMedCrossRef

Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol 17(5):548–558. doi:10.1016/j.ceb.2005.08.001 PubMedCrossRef

Fidler IJ, Gruys E, Cifone MA et al (1981) Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst 67(4):947–956PubMed

Lobo NA, Shimono Y, Qian D et al (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675–699PubMedCrossRef

Miki J, Rhim JS (2008) Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 11(1):32–39. doi:10.1038/sj.pcan.4501018 PubMedCrossRef

10.

Patrawala L, Calhoun T, Schneider-Broussard R et al (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12):1696–1708. doi:10.1038/sj.onc.1209327 PubMedCrossRef

11.

Hurt EM, Kawasaki BT, Klarmann GJ et al (2008) CD44+CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98(4):756–765. doi:10.1038/sj.bjc.6604242 PubMedCrossRef

12.

Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946–10951. doi:10.1158/0008-5472.CAN-05-2018 PubMedCrossRef

13.

Yu SC, Bian, XW (2008) Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev

14.

Hendrix MJ, Seftor EA, Seftor RE et al (1987) A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38(1–2):137–147. doi:10.1016/0304-3835(87)90209-6 PubMedCrossRef

15.

Hendrix MJ, Seftor EA, Seftor RE et al (1989) Comparison of tumor cell invasion assays: human amnion versus reconstituted basement membrane barriers. Invasion Metastasis 9(5):278–297PubMed

16.

Hurt EM, Klarmann GJ, Kawasaki BT et al (2008) Prostate cancer stem cells. In: Majumder S (ed) Stem cells and cancer. Springer, New York

17.

Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267–273. doi:10.1038/ng1180 PubMedCrossRef

18.

Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. doi:10.1073/pnas.0506580102 PubMedCrossRef

19.

Blalock EM, Geddes JW, Chen KC et al (2004) Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101(7):2173–2178. doi:10.1073/pnas.0308512100 PubMedCrossRef

20.

Funato N, Ohyama K, Kuroda T et al (2003) Basic helix-loop-helix transcription factor epicardin/capsulin/Pod-1 suppresses differentiation by negative regulation of transcription. J Biol Chem 278(9):7486–7493. doi:10.1074/jbc.M212248200 PubMedCrossRef

21.

Du L, Wang H, He L et al (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14(21):6751–6760. doi:10.1158/1078-0432.CCR-08-1034 PubMedCrossRef

22.

Klarmann GJ, Decker A, Farrar WL (2008) Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 3(2):59–63PubMed

23.

Liu S, Dontu G, Mantle ID et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66(12):6063–6071. doi:10.1158/0008-5472.CAN-06-0054 PubMedCrossRef

24.

Pan G, Thomson JA (2007) Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 17(1):42–49. doi:10.1038/sj.cr.7310125 PubMedCrossRef

25.

Morel AP, Lievre M, Thomas C et al (2008) Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS ONE 3(8):e2888. doi:10.1371/journal.pone.0002888 PubMedCrossRef

26.

Mani SA, Guo W, Liao MJ et al (2008) The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715. doi:10.1016/j.cell.2008.03.027 PubMedCrossRef

27.

Croker AK, Goodale D, Chu J et al. (2008) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med

28.

Loric S, Paradis V, Gala JL et al (2001) Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 37(12):1475–1481. doi:10.1016/S0959-8049(01)00143-5 PubMedCrossRef

29.

Cano A, Perez-Moreno MA, Rodrigo I et al (2000) The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2(2):76–83. doi:10.1038/35000025 PubMedCrossRef

30.

Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939. doi:10.1016/j.cell.2004.06.006 PubMedCrossRef

31.

Kwok WK, Ling MT, Lee TW et al (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65(12):5153–5162. doi:10.1158/0008-5472.CAN-04-3785 PubMedCrossRef

32.

Firulli BA, Redick BA, Conway SJ et al (2007) Mutations within helix I of Twist1 result in distinct limb defects and variation of DNA binding affinities. J Biol Chem 282(37):27536–27546. doi:10.1074/jbc.M702613200 PubMedCrossRef

33.

Karhadkar SS, Bova GS, Abdallah N et al (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431(7009):707–712. doi:10.1038/nature02962 PubMedCrossRef

34.

Zhu G, Zhau HE, He H et al (2007) Sonic and desert hedgehog signaling in human fetal prostate development. Prostate 67(6):674–684. doi:10.1002/pros.20563 PubMedCrossRef

35.

Feldmann G, Dhara S, Fendrich V et al (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67(5):2187–2196. doi:10.1158/0008-5472.CAN-06-3281 PubMedCrossRef

36.

Jothy S (2003) CD44 and its partners in metastasis. Clin Exp Metastasis 20(3):195–201. doi:10.1023/A:1022931016285 PubMedCrossRef

37.

Martin TA, Harrison G, Mansel RE et al (2003) The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46(2):165–186. doi:10.1016/S1040-8428(02)00172-5 PubMedCrossRef

38.

Omara-Opyene AL, Qiu J, Shah GV et al (2004) Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 84(7):894–907. doi:10.1038/labinvest.3700112 PubMedCrossRef

39.

Sheridan C, Kishimoto H, Fuchs RK et al (2006) CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59. doi:10.1186/bcr1610 PubMedCrossRef

40.

Yu Q, Stamenkovic I (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13(1):35–48. doi:10.1101/gad.13.1.35 PubMedCrossRef

41.

Paradis V, Eschwege P, Loric S et al (1998) De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol 51(11):798–802. doi:10.1136/jcp.51.11.798 PubMedCrossRef

42.

Fraser JR, Laurent TC, Laurent UB (1997) Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 242(1):27–33. doi:10.1046/j.1365-2796.1997.00170.x PubMedCrossRef

43.

Jiang WG (1999) Ezrin regulates cell–cell and cell–matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci 112(Pt 18):3081–3090PubMed

44.

Wu M, Bai X, Xu G et al (2007) Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. Proteomics 7(12):1973–1983. doi:10.1002/pmic.200600643 PubMedCrossRef

45.

Croker AK, Allan AL (2007) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12:374–390PubMedCrossRef

46.

Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827. doi:10.1038/nature04186 PubMedCrossRef

47.

Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66(9):4553–4557. doi:10.1158/0008-5472.CAN-05-3986 PubMedCrossRef

48.

Avigdor A, Goichberg P, Shivtiel S et al (2004) CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103(8):2981–2989. doi:10.1182/blood-2003-10-3611 PubMedCrossRef

49.

Weidt C, Niggemann B, Kasenda B et al (2007) Stem cell migration: a quintessential stepping stone to successful therapy. Curr Stem Cell Res Ther 2(1):89–103. doi:10.2174/157488807779317008 PubMedCrossRef

50.

Engl T, Relja B, Marian D et al (2006) CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia (New York, NY) 8(4):290. doi:10.1593/neo.05694

51.

Sun YX, Wang J, Shelburne CE et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89(3):462–473. doi:10.1002/jcb.10522 PubMedCrossRef

52.

Hermann PC, Huber SL, Herrler T et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323. doi:10.1016/j.stem.2007.06.002 PubMedCrossRef

53.

Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275–284. doi:10.1038/nrc1590 PubMedCrossRef

54.

Ponti D, Costa A, Zaffaroni N et al (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65(13):5506–5511. doi:10.1158/0008-5472.CAN-05-0626 PubMedCrossRef

55.

Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148–154. doi:10.1007/BF00300234 PubMedCrossRef

Title: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature
Authors: George J. Klarmann
Elaine M. Hurt
Lesley A. Mathews
Xiaohu Zhang
Maria A. Duhagon
Tashan Mistree
Suneetha B. Thomas
William L. Farrar
Publication date: 01-06-2009
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-009-9242-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Dietary stearate reduces human breast cancer metastasis burden in athymic nude mice

Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion

Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model

Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling

Pulmonary lymphangitic sarcomatosis and a review of the literature

NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer